<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259580</url>
  </required_header>
  <id_info>
    <org_study_id>REB18-0410</org_study_id>
    <nct_id>NCT04259580</nct_id>
  </id_info>
  <brief_title>Calgary Registry for Advanced and Therapeutic Endoscopy</brief_title>
  <acronym>CReATE</acronym>
  <official_title>Calgary Registry for Advanced and Therapeutic Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is to be a
      high-fidelity prospective multi-centre registry. The study population consists of consecutive
      adult ERCP patients from September 2018 to August 2022. Informed consent is acquired for each
      patient. All relevant pre-procedural, procedural, peri-procedural and post-procedural data
      are captured in real time by a full-time third-party research assistant directly observing
      procedures. Outcomes are ascertained by comprehensive medical record review and patient phone
      interview 30 days after the index procedure. This registry also serves as a secure data
      collection platform for several currently recruiting prospective studies and randomized
      trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Rate of unplanned healthcare utilization</measure>
    <time_frame>30 days</time_frame>
    <description>Composite outcome of post-ERCP pancreatitis, bleeding, cholangitis or sepsis, or any other adverse event deemed related to the index procedure, or emergency department presentation or inpatient admission within 30 days deemed related to the index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of post-ERCP pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <description>Typical abdominal pain with amylase/lipase 3 times normal or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post-ERCP bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Hematemesis and/or melena or hemoglobin drop 2 g or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post-ERCP cholangitis or sepsis</measure>
    <time_frame>30 days</time_frame>
    <description>Fever &gt; 38C for 24 hours or more with cholestasis, or positive blood cultures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rates</measure>
    <time_frame>Immediate</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Biliary Disease</condition>
  <condition>Pancreatic Diseases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic retrograde pancreatography (ERCP)</intervention_name>
    <description>Endoscopic procedure to access biliary and/or pancreatic structures</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients undergoing ERCP.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any standard indication for ERCP, in the absence of standard contraindications;

          -  age 18 years or over;

          -  ability and willingness to give informed consent to be included in the registry and/or
             to involvement in one (or more) prospective sub-studies, or accompaniment by a
             surrogate who is willing and able to provide consent.

        Exclusion Criteria:

        -none other than inverses of above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nauzer Forbes, MD, MSc</last_name>
    <phone>403-592-5089</phone>
    <email>nauzer.forbes@ucalgary.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nauzer Forbes, MD, MSc</last_name>
      <phone>403-592-5089</phone>
      <email>nauzer.forbes@ucalgary.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Diseases</mesh_term>
    <mesh_term>Gallbladder Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Future studies will utilize patient-specific data, which will be in a de-identified encrypted secure format whenever shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For 5 years after data collection is complete.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

